Sigma Life Science, the innovative biological products and
services business unit of
Sigma Aldrich Corporation
), has entered into an agreement with Olink Bioscience to
distribute Duolink In Situ products globally. The product
contains a new protein interaction analysis technology used for
imaging and measuring protein-protein interactions in unmodified
Per the agreement, Duolink products will work in sync with
Sigma Life Science's antibody portfolio and allow researchers to
target and analyze the precise protein of interest. The synergy
between the partners will help scientific community to access the
global support network and increase the adoption of the Duolink
The patented PLA technologies used in Duolink products enables
rapid detection of single protein-protein interactions and
recognition of relative changes in post-translational
This highly adaptable Duolink technology can be used along
with CompoZr Zinc Finger Nuclease-mediated gene editing to track
knocked-out or knocked-in genes. It can also be used with MISSION
RNA interference technologies to track protein expression
following gene knockdown.
Sigma-Aldrich is a leading life sciences company. A few days
ago, it released its fourth-quarter 2012 results. The company
posted adjusted earnings (excluding items) of 96 cents per share
in the quarter compared with the year-ago earnings of 91 cents
per share. The results beat the Zacks Consensus Estimate of 95
Profit, as reported, rose roughly 7% year over year to $116
million (or 96 cents per share) in the quarter from $108 million
(or 89 cents per share) a year ago. Acquisitions (including
BioReliance) and gains across overseas markets aided the results.
Revenues rose 7% year over year to $655 million in the quarter
but missed the Zacks Consensus Estimate of $660 million.
Sigma-Aldrich expects low-to-mid single digit organic sales
gain in 2013. It envisions adjusted earnings per share in the
band of $4.10 to $4.20 for the year.
Sigma-Aldrich's BioReliance acquisition and expansion
initiatives in Asia Pacific and other high growth markets are
expected to continue to add to its growth. However, the company's
research business is still facing economic challenges due to
uncertainties in the U.S. and Europe.
Sigma-Aldrich currently maintains a Zacks Rank #3 (Hold).
Other companies in the specialty chemical space with favorable
Zacks Rank are
American Pacific Corporation
). All of them hold a Zacks Rank #1 (Strong Buy).
AMER PAC CORP (APFC): Free Stock Analysis
(NVZMY): ETF Research Reports
PENFORD CORP (PENX): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.